Syndax Pharmaceuticals announced inducement awards granting stock options for up to 66,700 shares to four new employees as part of its 2023 Inducement Plan. These options vest over four years, with an initial 25% vesting after one year and the remainder monthly over the following three years, contingent on continued employment. This move supports Syndax's growth by attracting new talent to advance its cancer therapy pipeline, including FDA-approved drugs Revuforj® and Niktimvo™. The company continues clinical trials to expand treatment options in oncology.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Ecopetrol, Colombia's largest energy company, will announce its financial and operating results for the second quarter of 2026 on August 3 after market close. A virtual conference will follow on August 4, featuring simultaneous Spanish and English br...
Galaxy Digital reports that large Bitcoin holders (whales) have not sold their holdings over fears of quantum computing risks. Instead, concerns about quantum threats seem to influence institutional investors who are hesitant to buy Bitcoin. Recent l...
Visionstate Corp. has decided to pause its previously announced non-brokered private placement financing under the LIFE exemption, initially targeting $500,000 to $1,000,000. The company will use this time to reconsider the structure and timing of th...
